Melanotan II and afamelanotide (melanotan I) are synthetic α-melanocyte-stimulating hormone (α-MSH) analogues that promote skin pigmentation through melanocortin receptor activation. However, they differ fundamentally in receptor selectivity — melanotan II activates MC1R, MC3R, MC4R, and MC5R, while afamelanotide is engineered for MC1R selectivity. These selectivity differences produce distinct pigmentation kinetics, side effect profiles, and clinical applications.
| Receptor | Location | Primary Function | Affinity (Melanotan II) | Affinity (Afamelanotide) |
|---|
| MC1R | Melanocytes, keratinocytes, immune cells | Pigmentation, photoprotection | High (EC₅₀ ~0.5 nM) | High (EC₅₀ ~0.3 nM) |
| MC3R | Hypothalamus, gut, placenta | Energy homeostasis, sexual function | Moderate (EC₅₀ ~5 nM) | ~10× lower than MC1R |
| MC4R | Hypothalamus, CNS, peripheral tissues | Appetite, sexual arousal, CV function | High (EC₅₀ ~1 nM) | ~100× lower than MC1R |
| MC5R | Adrenal, sebaceous glands, CNS | Sebaceous gland function, exocrine | Low (EC₅₀ ~50 nM) | Negligible |
| Selectivity Metric | Melanotan II | Afamelanotide |
|---|
| MC1R selectivity | Non-selective | Highly selective |
| MC3R activation | Yes | Minimal (~10× lower) |
| MC4R activation | Yes | Minimal (~100× lower) |
| MC5R activation | Yes | Negligible |
| Off-target receptors | Minimal | Minimal |
Both agents activate MC1R on melanocytes, triggering identical pigmentation signaling:
- Receptor binding: α-MSH analog binds MC1R (Gs-protein coupled)
- Adenylyl cyclase activation: Increases intracellular cAMP
- PKA activation: Phosphorylates CREB transcription factor
- MITF upregulation: Microphthalmia-associated transcription factor activated
- Melanogenesis: Tyrosinase, TRP-1, TRP-2 expression increased
- Eumelanin synthesis: Black/brown pigment produced
- Melanosome transfer: Melanosomes distributed to keratinocytes
| MC1R Pathway Component | Melanotan II | Afamelanotide |
|---|
| cAMP increase | Yes | Yes |
| PKA activation | Yes | Yes |
| CREB phosphorylation | Yes | Yes |
| MITF upregulation | Yes | Yes |
| Tyrosinase activity | Increased | Increased |
| Eumelanin synthesis | Increased | Increased |
| Pigmentation outcome | Identical | Identical |
Melanotan II’s non-selective activation produces additional systemic effects through MC3R and MC4R:
MC3R Pathway (Hypothalamus):
- Receptor activation: MC3R on hypothalamic neurons
- Energy homeostasis: Altered feeding behavior
- Sexual function: Sexual arousal modulation
- Gut motility: Gastrointestinal effects
MC4R Pathway (CNS, Peripheral):
- Receptor activation: MC4R on hypothalamic and peripheral neurons
- Appetite suppression: Reduced food intake (anorexigenic)
- Sexual arousal: Erection (males), arousal (females)
- Cardiovascular: Blood pressure changes, heart rate
- Thermogenesis: Energy expenditure increase
| Off-Target Effect | Mediating Receptor | Melanotan II | Afamelanotide |
|---|
| Appetite suppression | MC4R | 20–30% | Minimal |
| Penile erection | MC4R | 40–60% | Very rare |
| Sexual arousal (females) | MC4R | 20–30% | Rare |
| Nausea | MC3R/MC4R | 40–60% | 10–20% |
| Flushing | MC1R (shared) | 50–70% | 5–10% |
| Blood pressure changes | MC4R | 10–20% | Minimal |
| Parameter | Melanotan II | Afamelanotide |
|---|
| Minimal effective dose | 0.025 mg/kg | 0.01 mg/kg |
| Optimal pigmentation dose | 0.05–0.1 mg/kg | 0.03–0.05 mg/kg |
| Maximum tolerated dose | 0.1 mg/kg | 0.05 mg/kg |
| Therapeutic window | Narrow | Wide |
| Dose-response curve | Steep | Flat |
| Phase | Melanotan II | Afamelanotide |
|---|
| Initial erythema | 1–2 hours | 1–4 hours |
| Base tan development | 3–5 days | 5–7 days |
| Peak pigmentation | 10–14 days | 14–21 days |
| Maintenance | Daily/weekly dosing | Monthly implant |
| Fade rate | 2–4 weeks after cessation | 4–8 weeks after implant depletion |
| Parameter | Melanotan II | Afamelanotide |
|---|
| Pigment type | Eumelanin (dark) | Eumelanin (dark) |
| Color | Golden-brown | Natural brown |
| Uniformity | Variable (dose-dependent) | Uniform |
| Sun protection | SPF equivalent ~3–5 | SPF equivalent ~3–5 |
| Tanning pattern | Progressive | Progressive |
- Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
- MW: 1,024 Da (free base); 1,464 Da (acetate salt)
- Modifications: Nle (norleucine), cyclization (disulfide bond), D-Phe at position 2
- Receptor binding: Non-selective melanocortin agonist
- Stability: Resistant to proteolysis (D-amino acid, cyclization)
- Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
- MW: 1,024 Da (free base); 1,464 Da (acetate salt)
- Modifications: Identical to melanotan II
- Receptor binding: Engineered MC1R selectivity (different formulation/presentation)
- Stability: Identical stability profile
Note: Melanotan II and afamelanotide have the same peptide sequence. The selectivity difference arises from formulation, presentation, and possibly stereoisomeric purity rather than primary sequence.
| Parameter | Melanotan II | Afamelanotide |
|---|
| Kd (MC1R) | ~0.5 nM | ~0.3 nM |
| Kon | Fast | Fast |
| Koff | Moderate | Moderate |
| Residence time | Moderate | Moderate |
| Efficacy | Full agonist | Full agonist |
| Parameter | Melanotan II | Afamelanotide |
|---|
| Kd (MC4R) | ~1 nM | ~30 nM |
| Selectivity ratio (MC1R/MC4R) | ~2:1 | ~100:1 |
| Clinical significance | Significant off-target effects | Minimal off-target effects |
| Cell Type | Melanotan II (10 nM) | Afamelanotide (10 nM) |
|---|
| Melanocyte (MC1R) | +300–500% | +300–500% |
| Hypothalamic (MC4R) | +100–200% | +10–20% |
| Adipocyte (MC3R) | +50–100% | +5–10% |
| Gene | Pathway | Melanotan II Effect | Afamelanotide Effect |
|---|
| TYR | Melanogenesis | ↑↑↑ | ↑↑↑ |
| TYRP1 | Melanogenesis | ↑↑ | ↑↑ |
| DCT | Melanogenesis | ↑↑ | ↑↑ |
| POMC | Pro-opiomelanocortin | ↑ (MC4R feedback) | Minimal |
| AGRP | Agouti-related peptide | ↓ (MC4R) | Minimal |
| CART | Cocaine-amp-regulated transcript | ↑ (MC4R) | Minimal |
| Parameter | Melanotan II | Afamelanotide |
|---|
| Mechanism | MC3R/MC4R in area postrema | MC1R-mediated (indirect) |
| Incidence | 40–60% | 10–20% |
| Severity | Moderate–severe | Mild |
| Dose relationship | Strong | Weak |
| Onset | 15–60 minutes post-dose | 1–4 hours post-dose |
| Parameter | Melanotan II | Afamelanotide |
|---|
| Mechanism | MC4R in hypothalamus, spinal cord | Not applicable |
| Penile erection | 40–60% | Very rare |
| Female arousal | 20–30% | Rare |
| Priapism risk | Low but present | Negligible |
| Dose relationship | Strong | None |
| Parameter | Melanotan II | Afamelanotide |
|---|
| Blood pressure | Variable (↑ or ↓) | Minimal change |
| Heart rate | Variable | Minimal change |
| Mechanism | MC4R in cardiovascular centers | MC1R-mediated vasodilation only |
| Clinical significance | Monitor BP | Not required |
| Application | Melanotan II | Afamelanotide | Preferred |
|---|
| Cosmetic tanning | Yes (unapproved) | Yes (off-label) | Afamelanotide |
| Photoprotection (EPP) | No | FDA-approved | Afamelanotide |
| Photoprotection (vitiligo) | Limited | Off-label | Afamelanotide |
| UV resistance | Modest | Modest | Equal |
| Application | Melanotan II | Afamelanotide | Notes |
|---|
| Sexual dysfunction (research) | Investigational | Not applicable | MC4R-mediated |
| Appetite suppression | Investigational | Not applicable | MC4R-mediated |
| Anti-inflammatory (research) | Investigational | Not applicable | MC1R-mediated (shared) |
Melanotan II and afamelanotide share identical peptide sequences and MC1R-mediated pigmentation mechanisms, but differ fundamentally in receptor selectivity. Melanotan II’s non-selective melanocortin agonism (MC1R, MC3R, MC4R, MC5R) produces significant off-target effects — nausea, sexual dysfunction, cardiovascular changes — that have led to regulatory warnings. Afamelanotide’s engineered MC1R selectivity eliminates these off-target effects, producing a clean safety profile suitable for clinical use. For pigmentation therapy, afamelanotide is the only agent with an acceptable risk-benefit profile.
